Is arterial hypertension of patients with IgA nephropathy well controlled?
Abstract
Background: Next to proteinuria, serum creatinine level, age and histopathological changes arterial hypertension (AH) is represents an important risk factor of kidney disease progression in patients with chronic kidney disease. The purpose of the present study was to assess the prevalence, treatment and control of AH in patients with IgA nephropathy (IgAN) according to Slovenian guidelines.
Methods: One hundred and ten patients with IgAN, hospitalized at Department of Nephrology in University Medical Center Ljubljana between January 2002 and December 2006, were enrolled in our retrospective study. Clinical data including systolic, diastolic blood pressure the day before renal biopsy, sex, age, family history of hypertension, 24-hour proteinuria and serum creatinine level were evaluated from medical documentation. The glomerular filtration rate was estimated by measured creatinine clearance, Cockcroft-Gault and MDRD Study equation. The number and the dose of antihypertensive drugs before renal biopsy and on the discharge were registered.
Results: Twenty-three (20.9 %) patients with IgAN were normotensive. 87 (79.1 %) patients had AH, among them only 13 (14.9 %) had blood pressure lower than 130/80 mm Hg. Patients with AH were older (p = 0.001), with higher 24-hour proteinuria (p < 0.002), serum creatinine level (p < 0.001), lower creatinine clearance (p < 0.004) and had more often family history of hypertension (p = 0.05). Before renal biopsy patients were treated with 0 to 4 antihypertensive drugs, on discharge from 1 to 6, among them number of angiotensinconverting enzyme inhibitors (ACEi) and angiotensin receptor antagonist (ARB) were increased (from 65.5 % to 80.4 %).
Conclusions: Ninety-seven percent of patients with IgAN had AH which was treated according to Slovenian guidelines in less than 15 %. The choice of ACEi and ARB drug groups was adequate, but the number and the dose of drugs should be increased for well-controlled blood pressure.
Downloads
References
Fofi C, Pecci G, Galliani M, Comunian MC, Muda AO, Pierucci A, et al. IgA nephropathy: multivariate statistical analysis aimed at predicting outcome. J Nephrol 2001; 14: 280–5.
D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36: 227–37.
Ikee R, Kobayashi S, Saigusa T, Namikoshi T, Yamada M, Hemmi N, et al. Impact of hypertension and hypertension-related vascular lesions in IgA nephropathy. Hypertens Res 2006; 29: 15– 22.
Bartostik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728–35.
Almartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991; 18: 12–9.
Remuzzi G, Chiurchiu C, Ruggenenti P. Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int 2004; 92 Suppl: 90–6.
Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–8.
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877–84.
Pisoni R, Remuzzi G. How much must blood pressure be reduced in order to obtain the remission of chronic renal disease? J Nephrol 2000; 13: 228–31.
Payton CD, McLay A, Jones JM. Progressive IgA nephropathy: the role of hypertension. Nephrol Dial Transplant 1988; 3: 138– 42.
Peterson JC, Adler S, Burkart JM, Greene T, Hebert L, Hunsicker L, et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Int Med 1995; 123: 754–62.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379–85.
Kanno Y, Okada H, Saruta T, Suzuki H. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow up. Clin Nephrol 2000; 54: 360–5.
Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol 2000; 11: 2395–403.
Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int 2006; 69: 1934–8.
Kveder R. Bolezni ledvic. In: Kocijančič A, Mrevlje F. Interna medicina. 2nd edition. Ljubljana: DZS d. d.; 1998. p. 738–920.
Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738–48.
Accetto R, Dobovišek J, Dolenc P, Salobir B. Slovenske smernice za obravnavo arterijske hipertenzije (2003). Zdrav Vestn 2004; 73: 507–17.
Guidelines Subcommitttee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 10011–53.
Eiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 2005; 9: 40–5.
Shidham GB, Siddiqi N, Beres JA, Logan B, Nagaraja HN, Shidham SG, et al. Clinical risk factors associated with bleeding after native kidney biopsy. Nephrology 2005; 10: 305–10.
Alpers CE. Kidney. In: Kumar V, Abbas AK, Fausto N. Robbins and Cotran: Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier Saunders; 2005. p. 955–1021.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serume creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–70.
Javna agencija RS za zdravila in medicinske pripomočke. Baza podatkov o zdravilih. Dosegljivo na: www.zdravila.net.
Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JWK. Secondary hypertension in blood pressure clinic. Arch Intern Med 1987; 147: 1289–93.
Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2001; 161: 1207–16.
Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int 2005; 99 Suppl: 25–9.
Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606–15.
Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients The data of the meta-analyses. J Am Soc Nephrol 2005; 16 Suppl: 58–63.
Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67: 799–812.
Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479–86.
Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291–7.
Fagard RH, Van den Enden M, Leeman M, Warling X. Survey on treatment of hypertension and implementation of World Health Organization/ International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297–302.
Accetto R. Vrednotenje nekaterih značilnosti – napovednih dejavnikov v prehipertenzivni fazi razvoja arterijske hipertenzije [doktorsko delo]. Ljubljana: Univerza v Ljubljani; 1995.
Goldstein IB, Shapiro D, Guthrie D. Ambulatory blood pressure and family history of hypertension in healthy men and women. Am J Hypertens 2006; 19: 486–91.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
